DOCSLIB.ORG

NOVATION Contents INDUSTRIALIZATION INDUSTRIALIZATION

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
NOVATION Contents INDUSTRIALIZATION INDUSTRIALIZATION NOVATION contents INDUSTRIALIZATION INDUSTRIALIZATION INTERNATIONALIZATIONDUSTRIALIZATION INNOVATIONINNOVATIONTERNATIONALIZATION 1、药促会131224.indd 2 2014/1/3 9:33:57 NOVATION contents 中国药促会简介 001 Brief Introduction of SINO-PhIRDA 机构设置 002 INDUSTRIALIZATIONOrganizational Structure of SINO-PhIRDA 桑国卫院士的贺信 003 Congratulatory Letter by Academician Sang Guowei 2012- 2013中国医药工业科研开发促进会工作报告(摘要） 007 SINO-PhIRDA Annual Work Report of 2012-2013 (Abstract) 第九届会员大会第四次会议纪要 014 Summary of 4th Meeting of 9th SINO-PhIRDA Assembly 会领导介绍 017 Instruction of SINO- PhIRDA Leadership 章程 DUSTRIALIZATION 020 INTERNATIONALIZATION Constitution of SINO-PhIRDA 第九届会员单位及其代表 025 Members of SINO- PhIRDA Ninth General Assembly 会员单位简介 027 Brief Introduction of SINO- PhIRDA Members 重要活动 081 Important Events 1.加强协会建设 082 Strengthen SINO- PhIRDA Construction 2.推动医药产业创新发展 087 Promote Innovation and Development of Pharmaceutical Industry 3.促进国际交流与合作 103 Enhance International Exchanges and Collaborations 大事记（2012.7-2013.10） 118 Remarkable Events (2012.7-2013.10) INNOVATIONINNOVATIONTERNATIONALIZATION 1、药促会131224.indd 1 2014/1/3 9:33:57 2013-2014 Association journal Founded in 1988, China Pharmaceutical Industry Research and Development Association (SINO- PhIRDA) is registered as a non-profitorganization by the Ministry of Civil Affair of China at the first national level. At current stage, SINO-PhIRDA has more than 60 members which are three major categories: First, national pharmaceuticalenterprises excelling at medical innovation; Second, universities, colleges and research institutions conducting pharmaceutical research and development;Third, clinical institutions featuring high skills in applicable research on new drugs,especially those undertake “major new drug innovation” technological platform for good clinical practice. SINO-PhIRDA will exert great effort to grow into a social organization featuring “university- industry collaboration”, an organization which centers on research 简 介 and development, persists in innovation to achieve unmet clinical requirements. BRIEF INTRODUCTION Major work of SINO- PhIRDA includes: First, to promote communication and innovative development of our member units 中国医药工业科研开发促进会（简称中国药促会，英文名称为China and even the whole pharmaceutical industry through forums, press- Pharmaceutical Industry Research and Development Association， conferences, summits, etc; Second, to make efforts to establish 英文缩写为SINO-PhIRDA）成立于1988年，是经国家民政部登记注册的 an international exchange platform for our member units through 非营利性全国性一级社会团体组织。 cooperation with foreign embassies and foreign associations such 目前，中国药促会有会长及会员单位60多家，主要由三方面的成员构 as PhRMA to stimulate communication between China and foreign 成：一是，在医药创新方面具有代表性的民族医药企业；二是，从事医药 countries in pharmaceutical field; Third, to improve the website 研发的高等院校和科研院所；三是，在新药临床研究领域具有较高水平、 of SINO-PhIRDA and provide collecting, arranging, revising and 特别是承担“重大新药创制”科技重大专项新药临床评价研究（GCP）技 consulting service of pharmaceutical information, which includes 术平台的临床医疗机构。中国药促会将努力建设成为以研发为核心，以创 the following internal e-magazines such as the bimonthly journal 新为宗旨，以临床需求为导向，“产学研用”紧密结合的促进医药科研开 Scientific and Technological Development Information on Pharmacy, 发的社会团体。 Daily Pharmaceutical Information Brief, Weekly International 中国药促会的工作内容主要包括：一是，通过举办各种论坛、发布 Pharmaceutical Development Tendency and Research Information 会、大型会议等促进会员单位乃至整个医药产业互相交流、创新发展；二 Brief; Fourth, to conduct pharmaceutical policy research, propose 是，通过与美国药品研发和制造商协会（PhRMA）等国外协会和外国驻 valuable suggestions on healthcare reform and the development 华使馆合作，共同寻求推动中外医药产业领域的合作交流，为会员单位搭 of pharmaceutical industry , with the help from the National Health 建国际交流平台；三是，为会员单位提供医药信息搜集、整理、评价、咨 and Family Planning Commission(of the people’s Republic of 询的服务，包括编辑双月刊刊物《医药科研开发信息》和每日《医药信息 China) Ministry of Commerce, Ministry of Industry and Information 简报》、每周《国际医药产业发展动态与研发信息简报》、《行业热点评 Technology, CFDA and other concerned government departments. 析》等内部电子刊物以及建设中国药促会官方网站等内容；四是，开展医 Focusing on the principle of “innovation,industrialization,int 药政策研究工作，在卫生计生委、商务部、工信部、国家食品药品监督管 ernationalization”, SINO-PhIRDA will strengthen self-discipline, 理总局等有关政府部门和医药科研学术机构和企业的支持下，为医改事业 promote technological progress for and enhance healthy 和医药产业发展建言献策。 development of our national pharmaceutical industry, making 中国药促会将围绕 “创新、产业化、国际化”的宗旨，加强行业自 constant contributions to the greater economic development of our 律，推动我国医药行业的技术进步，促进我国医药产业健康发展，为加快 country and public health. 我国经济社会发展、保障人民群众健康不断做出贡献！ 01 中国医药工业科研开发促进会 China Pharmaceutical Industry Research and Development Association 1、药促会131224.indd 1 2014/1/3 9:33:58 2013-2014 Association journal 机构设置 ORGANIZATIONAL STRUCTURE OF ASSOCIATION 会员大会 The Member's Assembly 会长会议 President Board Meeting Development Research Centre Medical and Pharmaceutical Industry 医药产业发展研究中心 秘书处 Secretariat (Human Resource Dept) Administrative Office 办公室 Accounting Dept 财务部 Ressarch Dept 研究部 Information Dept 信息部 Cooperation Dept International 国际部 （人力资源部） 中国医药工业科研开发促进会 China Pharmaceutical Industry Research and Development Association 02 1、药促会131224.indd 2 2014/1/3 9:33:58 2013-2014 Association journal 致中国医药工业科研开发促进会 第九届会员大会第四次会议的贺信 不断提升会员的服务质量。这是十分值得肯定的！ 同时，中国药促会为维护行业的利益，不断 为医药产业健康发展发出声音。先后针对广东省药 品交易规则征求意见稿和上海市医保药品试行“带 量采购”实施方案征求意见稿提出修改建议，得到 了业界的广泛关注和积极响应，已经产生了一定的 影响作用。 党的十八大明确提出“实施创新驱动发展 战略”和“加快建设国家创新体系，着力构建以 企业为主体、市场为导向、产学研相结合的技术 十一届全国人大常委会副委员长 创新体系”。增强新药创制能力被列为医药工业 中国工程院院士 “十二五”规划中的首要任务。在前不久举行的第 中国药促会荣誉会长 九次中共中央政治局集体学习会，专门以实施创新 桑国卫 驱动发展战略为主题，习近平总书记在会上提出了 如何加强创新发展的5个方面的任务。十二五期间 是我国医药创新发展的重要时期，是落实十八大精 各位代表： 神的开局之时。在新的一年里，希望中国药促会乘 在中国医药工业科研开发促进会第九届会员 着国家鼓励创新的东风，继续围绕“创新、产业 大会第四次会议召开之际，我向大会表示热烈的祝 化、国际化”的宗旨，顺应形势，真正成为中国民 贺！由于国家安排我于本月15至23日率团访问巴 族医药产业创新企业的代表性团体。 西，无法到会与大家见面，衷心希望大家能够谅 我也衷心希望中国药促会的各个会员单位认 解。 真贯彻落实十八大创新驱动发展战略，加强创新， 中国药促会九届三次会员大会以来，秉承 加强自律，积极参与中国药促会的各项工作，为改 “创新、产业化、国际化”宗旨，坚持民主决策， 善我国医药创新市场环境与促进我国医药创新发 实行科学规范管理，得到了会员单位和医药界的肯 展、提高人民的健康保障水平做出应有的贡献！ 定。我和大家都感到很欣慰。 祝会员大会取得圆满成功！ 在过去的一年里，中国药促会围绕“创新药 物的审批政策研究”和“创新药物的市场环境建 桑国卫 设”两大工作重点，配合政府有关部门开展专项研 二O一三年十月十七日 究工作，研究领域涉及“重大新药创制”知识产 权保护、创新药物审批机制、仿制药一致性评价 政策、医保用药管理、基本药物法律制度等多个方 面。通过开展课题探究、专题研讨会、地方调研等 方式，为完善和构建我国医药政策环境体系作出了 不懈的努力。同时还加强国际交流活动和提高信息 服务水平，探索更多渠道、采用更多样化的方式， 03 中国医药工业科研开发促进会 China Pharmaceutical Industry Research and Development Association 1、药促会131224.indd 3 2014/1/3 9:34:00 2013-2014 Association journal 致“2013国际医药创新大会”的贺信 十一届全国人大常委会副委员长、中国工程院院士 中国药促会荣誉会长 桑国卫 参加“2013国际医药创新大会”的各位 的战略支撑，必须摆在国家发展全局的核心位 环节提供政府、企业、专家交流互动的机会，而 嘉宾： 置”，“把全社会智慧和力量凝聚到创新发展上 且还设立了药物研发技术分论坛和商业桥，让参 在由中国国际商会、中国医药工业科研开 来”。9月30日，国家主席习近平强调，要敏锐 会者了解到临床试验设计、临床数据管理、生物 发促进会、药物信息协会、中国医疗保险研究 把握世界科技创新发展趋势，切实把创新驱动发 仿制药等相关问题的国际前沿动态，并为参会企 会、北京市卫生局、北京市食品药品监督管理局 展战略实施好。他就此还为发展科技创新提出了 业提供了来自加拿大、波兰、丹麦等国家的几十 主办的“2013国际医药创新大会”召开之际， 五方面任务：一是着力推动科技创新与经济社会 个研发项目。会议内容可谓丰富，实用。 我向大会表示热烈的祝贺！我已经为本次大会认 发展紧密结合；二是着力增强自主创新能力；三 促进医药技术创新，加快培育健康可持续 真准备了关于我国创新医药产业发展的报告。但 是着力完善人才发展机制；四是着力营造良好政 发展的医药产业，已经成为全球的共识。2013 是，由于我根据国家安排,本月15至23日率团出 策环境；五是着力扩大科技开放合作。 国际医药创新大会的召开，将极大鼓舞和促进中 访巴西，无法到会，衷心希望大家能够谅解。 医药科技创新能够提升医药产业健康可持 外医药产业界的交流与合作！我衷心地希望与会 本次大会的主题是鼓励医药创新，优化医 续发展的核心竞争力和根本驱动力。我们都很高 的医药界同仁能够都有所得，共同努力，为改 药创新的生态环境。中国政府一直重视医药产业 兴地了解到，这次大会将为医药创新活动提供一 善全球医药创新市场环境与促进全球医药创新发 的创新发展，中国共产党十八大作出了实施创新 个非常好的沟通和合作的平台。大会不仅设立 展、提高人类的健康保障水平做出应有的贡献！ 驱动发展战略的重大部署，十八大报告中也明 药物政策专题讨论，从药品审批、医疗保险、定 祝大会取得圆满成功！ 确：“科技创新是提高社会生产力和综合国力 价、招标、知识产权保护等医药创新相关的多个 桑国卫 二O一三年十月十八日 中国医药工业科研开发促进会 China Pharmaceutical Industry Research and Development Association 04 1、药促会131224.indd 4 2014/1/3 9:34:00 2013-2014 Association journal Congratulatory Letter to The Fourth Meeting of 9th SINO-PhIRDA General Assembly Sang Guowei Vice Chairman of the Standing Committee of Eleventh National People's Congress Honorary Chairman of SINO-PhIRDA, Academician of Chinese Academy of Engineering October 17,2013 Dear Representatives: conducting research, workshops/ seminars, pharmaceutical industry in China. During the local investigations, etc. Meanwhile, recent meeting of CPC Central Committee, I would like to express my sincere the Association promotes international General-Secretary Xi Jinping has pointed congratulations to the Fourth Meeting of 9th exchange and cooperation, as well as out five tasks to promote the innovation- SINO-PhIRDA General Assembly. According information service standard to constantly driven developments. The Twelfth Five- to the nation’s arrangements, I have to lead improve the quality of member services in Year Plan period is an important time for a delegation to visit Brazil during October 15- more diversified manners and approaches. the innovative development of Chinese 23, and I sincerely thank your understanding This is worthy of recognition. on my absence. pharmaceutical industry and to implement the spirit of the 18th National Congress of th At the same time, SINO-PhIRDA Since the Third Meeting of 9 SINO- the Communist Party of China. In next year, continues to make suggestions to promote PhIRDA General Assembly, we are happy I hope SINO-PhIRDA will take advantage the healthy development of pharmaceutical to see that the association focuses on of the encouraging policies for innovation, industry in order to safeguard the interests the goal of “Innovation, Industrialization, continue to focus on the goal of “Innovation, of the industry. The association suggested Internationalization”, adheres to the Industrialization, Internationalization” and changes to “Pharmaceutical Trading principle of democratic decision-making, become the organization representing Rules in Guangdong Province (Draft)” and implements scientific and standardized China’s domestic innovative “Implementation Plan for Drug Purchase management, which received good pharmaceutical
Load more

Recommended publications
  • Pharma China0409-285.P65
    TM C O N T E N T S ○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○ ○○○ I s s u e Editorial Mentholatum sues XiAn Meichen over Market Dynamics Brew New Order for trademark infringements 14 Chinese Pharma 2 API/Bulk Drugs 32 News in Focus Huaxing expands capacity of Amoxicillin MOH releases results of the 4th and 6-APA 14 APRIL National Health Service Survey 4 NCPG/DSM likely to build major The Market antibiotic API facility in Changchun 14 2 0 0 9 Data Snaptshot: Chinese OTC Shandong Antibiotics granted Germany healthcare market 5 GMP certification 15 Nicholas Hall reports slower growth Hisun sees profits up sharply in 2008 15 of OTC GI market in China 5 Changzhou Yabang-QH builds new In This Issue Industry News cGMP API plant with help from J&J 15 Chinese pharma industry perfor- Shijiazhuang Pharma receives EDQM MNCs report another year of mance in 2008 and outlook in 2009 5 certification for Vitamin B12 15 sharp revenue growth in China MNCs report another year of sharp India likely to investigate China’s 6-APA 15 Many MNCs experienced growth 20% revenue growth in China 6 MOC issues list of authorized exporters or more in China last year amid global MNCs positions for the huge diabetes of ephedrine drugs 15 slowdown P6 market potential in China 6 Data Snapshot - COS certifications and Harbin Pharma reconsiders Chinese producers likely to emerge DMFs held by Chinese companies 16 overseas IPO as global players of recombinant Chinese API in 2008 – Output and Export In preparation, Harbin Pharmaceutical human insulin 6 Volumes Down 16 Group is working on major and minor M&A is likely to intensify for retail Product and R&D News acquisitions this year P8 pharmacy sector in 2009 7 AOB to initiate clinical trials of TCM drug Pfizer opens new sterile facility Guangzhou introduces online for UI in the U.S.
    [Show full text]
  • China Pharmaceutical Newsletter
    Volume VII 2011 CHINA PHARMACEUTICAL ڵNEWSLETTER З֡Ԛ哦֡ଢ଼рࡗЗ แྼჯ)ཀৄDž዆ᄱᆶ၌ࠅິ SFDA Commissioner Shao Mingli SFDA Deputy Commissioner Wu Zhen of NPC Standing Committee attended the met with new Cuban Ambassador to meets the Head of Iran's Innovation and meeting. Chen Zhu, the Health Minister China On September 29, 2011, Shao Technology Cooperation Center On the & Chairman of the Forum attended the Mingli, Commissioner of SFDA met morning of September 6, 2011, Wu Zhen, forum and delivered a speech. with Mr. ALberto Jesus Blanco Silva, the SFDA Deputy Commissioner, met with the Chen Zhu said in his speech, through new Cuban Ambassador Extraordinary visiting Mr. Hamidreza Amirinia, Head of 30 years of reform and opening up, and Plenipotentiary to China, and his Innovation and Technology Cooperation China's GDP has maintained a 10% entourage in Beijing. The two sides Center of Iran. Both parties exchanged growth in 30 consecutive years, and held in-depth discussions on further views on enhancing mutual exchanges and created an economic miracle. In 2010, strengthening the bilateral cooperation in understanding, and promoting cooperation China's GDP had ranked second in the WKH¿HOGVRIELRORJLFDl products and drug LQWKH¿HOGRIWUDGLWLRQDO&KLQHVHPHGLFLQH world. In the 21st century, the Chinese safety supervision. (September 30, 2011) and biopharmaceuticals. (September 8, 2011) Government pays more attention to social SFDA Deputy Commissioner Wu development, taking the alleviation of SFDA Deputy Commissioner Bian Zhen meets the delegation of MHLW On poverty and improvement of health care, Zhenjia attends the APEC LSIF Drug the morning of August 23, 2011, Wu Zhen, education, housing, and employment, etc.
    [Show full text]
  • Download Table of Contents [PDF 1
    Advances in Biopharmaceutical Technology in China, Second Edition October 2018 Editors: Vicky (Qing) Xia, Leo (Yang) Cai BioPlan Associates, Inc. Rockville, MD Society for Industrial Microbiology and Biotechnology Fairfax, VA BioPlan Associates, Inc. 2275 Research Blvd., Ste. 500 Rockville MD 20850 USA 301-921-9074 www.bioplanassociates.com and Society for Industrial Microbiology and Biotechnology 3929 Old Lee Highway Suite 92A Fairfax, VA 22030-2421 703-691-3357 www.simbhq.org Copyright © 2018 BioPlan Associates, Inc. All rights reserved, including the right of reproduction in whole or in part in any form. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the written permission of the publisher. For information on special discounts or permissions contact BioPlan Associates, Inc. at 301- 921-5979, or [email protected] Editors: Vicky (Qing) Xia, Leo (Yang) Cai Project Director: Donnie E. Gillespie U.S. Editor: Terrell R. Otis Cover Design: LI Huijun Text Design: Esperance Shatarah, ES Design ISBN 978-1-934106-34-1 Front Cover Photo Courtesy of WuXi, by permission ii Acknowledgment This project would not have been possible without the exceptional efforts of the many people involved. In particular, we would like to thank our reviewers, whose expertise ensured this volume addressed today’s most important issues: ■ Tiffany M. Bauguess (Beeson), Consultant, MScGlobal Trials HK ■ Randy Berholz, Executive Vice President, Corporate Development and General Counsel, Innovus Pharmaceuticals, Inc. ■ David Deere, Chief Commercial Officer, PaizaBio ■ Changming Fang, Director of Biology and Drug Discovery, FronThera US Pharmaceuticals ■ Steve Ferguson, Chair, Department of Technology Transfer, Foundation for Advanced Education in the Sciences (FAES) Graduate School ■ Sean Hu, Founder, mAbKey Therapeutics ■ Charles (Changhui) Li, MS MBA, Chief Business Officer, Zhejiang Hopstem Biotech- nology Co., Ltd.
    [Show full text]
  • Pharmaceutical Innovation in the APAC Region
    Special report Pharmaceutical innovation in the APAC region A quantitative company ranking and future outlook Country/ Major Pharma Early-stage Drug Rank Company Maturity Total Score Region HQ (Top 50 by global revenue) Partnering Development 가장 혁신적인 1 Daiichi Sankyo Co Ltd Japan 410 320 135 865 대형 제약사 2 Takeda Pharmaceutical Co Ltd Japan 395 320 135 850 Rank 1-18 3 Eisai Co Ltd Japan 350 320 135 805 4 Astellas Pharma Inc Japan 345 320 135 800 5 Otsuka Holdings Co Ltd Japan 325 315 135 775 6 Shionogi & Co Ltd Japan 320 315 125 760 6 CSL Ltd Australia 345 310 105 760 8 Ono Pharmaceutical Co Ltd Japan 320 310 125 755 9 Mitsubishi Chemical Holdings Corp Japan (Mitsubishi Tanabe) 300 315 125 740 9 Kirin Holdings Co Ltd Japan (Kyowa Hakko Kirin) 315 300 125 740 11 Hanmi Pharmaceutical Co Ltd South Korea 325 295 115 735 12 Daewoong Pharmaceutical Co Ltd South Korea 305 300 95 700 13 Sumitomo Chemical Co Ltd Japan 265 305 125 695 14 FUJIFILM Holdings Corp Japan 265 300 125 690 15 Kyorin Holdings Inc Japan 280 280 105 665 16 Teijin Ltd Japan 250 275 115 640 17 Japan Tobacco Ltd Japan 230 260 115 605 18 Lupin Ltd India 185 280 125 590 18 Maruho Co Ltd Japan 200 265 125 590 Shanghai Fosun Pharmaceutical 18 Mainland China 175 305 110 590 (Group) Co Ltd Note: Scores do not reflect recent changes in company ownership, e.g., divestiture of CJ Healthcare to Korea Kolmar Holdings in 2018.
    [Show full text]
  • Simcere Pharmaceutical Group Limited 先聲藥業集團有限公司 (The “Company”) (A Company Incorporated in Hong Kong with Limited Liability)
    The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Simcere Pharmaceutical Group Limited 先聲藥業集團有限公司 (the “Company”) (a company incorporated in Hong Kong with limited liability) WARNING The publication of this Application Proof is required by The Stock Exchange of Hong Kong Limited (the “Exchange”) and the Securities and Futures Commission (the “Commission”) solely for the purpose of providing information to the public in Hong Kong. This Application Proof is in draft form. The information contained in it is incomplete and is subject to change which can be material. By viewing this document, you acknowledge, accept and agree with the Company, its joint sponsors, advisers or members of the underwriting syndicate that: (a) this document is only for the purpose of providing information about the Company to the public in Hong Kong and not for any other purposes. No investment decision should be based on the information contained in this document; (b) the publication of this document or supplemental, revised or replacement pages on the Exchange’s website does not give rise to any obligation of the Company, its joint sponsors, advisers or members of the underwriting syndicate to proceed with an offering in
    [Show full text]
  • Pharma China-201012.P65
    TM C O N T E N T S ○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○ ○○○ I s s u e Editorial The 4th Joint ChP-USP International MNCs escalates China deals and Symposium held in Hangzhou 20 investments in the face of increased API/Bulk Drugs News short term risks 2 52 Esteve Pharma forms API joint venture News in Focus with Hangzhou Huadong Pharma 20 December Health Minister Chen Zhu delivers Pharma industry cooperation under 6 speech on public hospital reform discussion between leading Chinese and Essential drug policy under pressure Indian trade groups 20 2 0 1 0 for revision 6 Product and R&D News Essential drug price cut likely to be New report: pharma becomes more active postponed to next year 6 in R&D in Asia-Pacific 21 In This Issue China to expedite pharma industry Monitor Group: China to Become Life restructure under new policy document 7 Science Powerhouse by 2020 21 SinoPharm confirms IPO for CNBG The Market General Health McKinsey: Chinese healthcare market SinoPharm Group plans an independent Vice Premier Li Keqiang pushes for to reach US$600 billion in ten years 7 IPO for China National Biotechnology steady healthcare reform progress 22 Group and its six subsidiary institutes. P11 SMEI releases Chinese pharma China will integrate different basic medical industry and market forecasts 8 Sanofi-Aventis to acquire BMP insurance programs 22 IMS: China to overtake Japan as the Sunstone CHA: China's surveillance network for 2nd largest drug market in 2015 8 Sanofi-Aventis and BMP Sunstone rational drug use in preliminary shape 22 China offers great prospects for out- entered into an agreement whereby MOH launch new measures to fight rebound sourcing of preclinical and toxicology Sanofi would acquire 100% of BMP of commercial briberies in hospitals 22 Sunstone for US$520.6 million.
    [Show full text]
  • China Regulatory and Market Access Pharmaceutical Report 2014
    CHINA REGULATORY AND MARKET ACCESS PHARMACEUTICAL REPORT 2014 Pacific Bridge Medical 7315 Wisconsin Avenue, Suite 609E Bethesda, MD 20814 Tel: (301) 469-3400 Fax: (301) 469-3409 Email: [email protected] Copyright © 2014 Pacific Bridge Medical. All rights reserved. This content is protected by US and International copyright laws and may not be copied, reprinted, published, translated, resold, hosted, or otherwise distributed by any means without explicit permission. Disclaimer: the information contained in this report is the opinion of Pacific Bridge Medical, a subsidiary of Pacific Bridge, Inc. It is provided for general information purposes only, and does not constitute professional advice. We believe the contents to be true and accurate at the date of writing but can give no assurances or warranties regarding the accuracy, currency, or applicability of any of the contents in relation to specific situations and particular circumstances. CHINA REGULATORY AND MARKET ACCESS PHARMACEUTICAL REPORT (2013) TABLE OF CONTENTS I. China Pharmaceutical Industry Overview .......................................................5 A. Overview B. China Pharmaceutical Market Trends C. China’s Pharmaceutical Distribution System D. Brief Overview of China’s Pharmaceutical Regulations E. China Food and Drug Administration (CFDA) II. The China Healthcare System .........................................................................13 A. History of China’s Healthcare System B. Struggling Healthcare Services Sector C. 2009 Healthcare Reform D. Hospitals and Medical Resources 1. Hospitals in China 2. Current Problems in the Hospital Sector 3. Private Investment in the Hospital Sector 4. Hospital Reform E. Health Insurance in China III. Drug Registration Regulations ........................................................................21 A. Drug Registration Policy B. Classification of Drugs C. Drug Registration Applications D. Application Documents for New Drug Registration E.
    [Show full text]
  • SIMCERE PHARMA GROUP [E/O] CRC: 41999 BOMH02229 001.00.00.00 0/4 H02229.SUB, Docname: 20-F, Doc: 1, Page: 1 *H02229/001/4* Description: FORM 20-F EDGAR 2
    BOWNE INTEGRATED TYPESETTING SYSTEM Site: BOWNE OF HONG KONG Phone: 852-2526-0688 Operator: BOM99999T Date: 24-JUN-2008 06:44:06.22 Name: SIMCERE PHARMA GROUP [E/O] CRC: 41999 BOMH02229 001.00.00.00 0/4 H02229.SUB, DocName: 20-F, Doc: 1, Page: 1 *H02229/001/4* Description: FORM 20-F EDGAR 2 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2007 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 0/4 Commission file number: 001-33398 Date: 24-JUN-2008 06:44:06.22 Simcere Pharmaceutical Group 001.00.00.00 (Exact name of Registrant as specified in its charter) Operator: BOM99999T N/A (Translation of Registrant’s name into English) H02229 Cayman Islands (Jurisdiction of incorporation or organization) BOM *H02229/001/4* No. 699-18 Xuan Wu Avenue, Phone: 852-2526-0688 Xuan Wu District, Nanjing Jiangsu Province 210042 People’s Republic of China (Address of principal executive offices) Zhigang Zhao Chief Financial Officer No. 699-18 Xuan Wu Avenue, Xuan Wu District, Nanjing CRC: 41999 EDGAR 2 Jiangsu Province 210042 People’s Republic of China Tel: (86) 25 8556 6666 x 8818 Fax: (86) 25 8547 7666 Site: BOWNE OF HONG KONG [E/O] E-mail:
    [Show full text]
  • Tender Watcher – Drugs: Guangdong Tender Rules Changed Again (For
    MORGAN STANLEY RESEARCH ASIA/PACIFIC Morgan Stanley Asia Limited+ Bin Li [email protected] +852 2239 7596 Yolanda Hu [email protected] +852 2848 5649 Isabella Zhao May 19, 2013 [email protected] +852 2848 5887 Tender Watcher – Drugs Guangdong tender rules Tender is a distinctive pricing mechanism for medical products in changed again (for worse?) China and an important lead indicator for product sales and corporate earnings. We launched Tender Watcher to provide updates on a regular basis. Déjà Vu Anhui + Fujian model? The much anticipated Guangdong (GD) provincial drug tender has taken another turn. Based on the newly issued draft guidelines, the GD tender could look like the combination of Anhui, Related Reports Fujian and Chongqing tenders. The good news is our BHC 92 Time to Watch Fujian Tender Price for Non-EDL Drugs industry experts do not believe this current proposal (i.e., August 25, 2011 more focus on price than quality) will be implemented, BHC 93 Key Takeaways from Expert Call on Fujian Drug Tender because this is the first draft for public opinion and will September 27, 2011 likely draw much pushback from the pharma industry, as BHC 98 Jiangsu EDL Tender Shows Positive Signs (Albeit Early) the Anhui model did in 2011. We plan to monitor the November 7, 2011 progress closely, given the importance of Guangdong. BHC 103 Anhui Model Sequel: EDL Marches to Big Hospitals December 6, 2011 What’s new: Guangdong govt. issued the draft TW 10 Tenders May Come In ‘12 guidelines for non-EDL and EDL drugs on May 17, and February 21, 2012 confirmed plans to use the Medicine Exchange for future TW Anhui Non-EDL Tender May Be Modified In Positive Direction tenders (see “Tender Watcher: Surprising twist in February 24, 2012 Guangdong - Bye to tender?”, March 20, 2013).
    [Show full text]
  • New Landscape of Pharmaceutical Manufacturing in China.Pdf
    ——New Landscape Of Pharmaceutical Manufacturing In China OCT. 12 ‐13, 2010 | InterContinental Hotel Shanghai | China 2010 Highlights & Reviews Strategical topics for the local and oversea pharmaceutical manufacturing giants Global manufacturer ‐ outsourcing concern and criteria? Supporting the sustainable Implementation of operational excellence Local manufacturer's 3‐ 5 years capacity strategy ‐ how to moving up the value chain? China latest drug reform, new GMP standard and technology transfer issues Facilitating and Achieving QbD for drug products. Green manufacturing strategies ‐ Harnessing the opportunities for cost reduction. PAT, process Improvement and cost reduction. Developing a flexible, multi‐product manufacturing strategy. Creating the pharmaceutical facility of the future. In 2009, AstraZeneca announced the company would further expand its supplying base in Wuxi and have more products locally produced in China. In 2009, Eli Lilly unveiled an over 40 million USD investment for expanding its facility in Suzhou, Jiangsu Province, China. With an area of 50,000 sqm, the expanded facility will manufacture Lilly’s insulin products, a function separate from the old facility which will be utilized fully for producing the cephalosporin formulations of Lilly. In 2009, Sanofi‐aventis announced that the company will relocate its current manufacturing facility from downtown Hangzhou and build a new manufacturing site in Binjiang New Development Zone. Involving an investment of 270 million RMB (31 million Euro), the new site is scheduled to be completed by 2012 and have an expanded capacity of 160 million packs. With an area of 44,775 square meters, the new site also allows the potential for further expansion and the creation of an export hub to other Asian countries.
    [Show full text]
  • Simcere Pharmaceutical Group (2096 HK) BUY (Initiation)
    5 Jan 2021 CMB International Securities | Equity Research | Company Initiation Simcere Pharmaceutical Group (2096 HK) BUY (Initiation) Transitioning from generic to innovative Target Price HK$13.84 Up/Downside +59.07% Current Price HK$8.70 China-based pharmaceutical company with global presence. Simcere Pharmaceutical Group Limited ("Simcere") was listed on the NYSE in 2007, as the first Chinese bio and chemical pharmaceutical company listed on the China Healthcare Sector NYSE, and completed privatization in 2013. Simcere is rapidly transitioning to an innovation and R&D-driven pharmaceutical company, leveraging its Jill Wu, CFA leading manufacturing and commercial capabilities. (852) 3900 0842 [email protected] Diversified product portfolio. Simcere has established a diversified product portfolio comprising five products for the treatment of oncology diseases, three Sam Hu, PhD products for the treatment of central nervous system diseases, five products (852) 3900 0882 for the treatment of autoimmune diseases, three products for the treatment of [email protected] cardiovascular diseases, 16 products for the treatment of bacterial or virus- related infectious diseases and a number of products for the treatment of other diseases. Core products include Endostar (an innovative biological drug for Mkt. Cap. (HK$ mn) 22,695 Avg. 3mths t/o (HK$ mn) N/A oncology), Iremod (an innovative chemical drug for auto-immune diseases), 52W High/Low (HK$) 11.68/7.65 Bicun (a CNS drug), etc. Total Issued Shares (mn) 2,609 Source: Bloomberg Rich innovative drug pipelines. Simcere has established three R&D centres in Nanjing (the Jiangsu Province), Shanghai and Boston (the US), respectively.
    [Show full text]
  • 2020 Interim Results Presentation
    Disclaimer The sole purpose of this Presentation (the “Presentation”) is to assist the recipient in deciding whether it wishes to proceed with a further investigation of Sihuan Pharmaceutical Holdings Group Ltd. (the “Company”) and it is not intended to form the basis of any decision to purchase securities, interests or assets in or of the Company. This Presentation does not constitute or contain an offer or invitation or recommendation or solicitation for the sale or purchase of securities, interests or assets in or of the Company and neither this document nor anything contained herein shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. Any decision to purchase or subscribe for securities in any offering must be made solely on the basis of the information contained in the prospectus or offering circular issued by the company in connection with such offerings. All the information in this Presentation has been provided by the Company and has not been independently verified. No representation or warranty, express or implied, is or will be made in or in relation to, and no responsibility or liability is or will be accepted by the Company or any of its subsidiaries as to the appropriateness, accuracy, completeness or reliability of, this Presentation or any other written or oral information made available to any interested party or its advisers and any liability therefore is hereby expressly disclaimed. And no reliance should be placed on the accuracy, fairness, completeness or correctness of the information contained in this Presentation. This Presentation is only being made available to parties who have signed and returned a confidentiality agreement and recipients are therefore bound by the confidentiality agreement in respect of all information contained herein.
    [Show full text]